Looks like Viking is moving their or-l obesity dr-g into late-stage trials later this year, and many folks seem to think this is actual momentum, not just hype. It certainly makes you wonder if this could lead to something bigger down the road like partnerships or real pipeline value.
There are no replies in this thread yet. Be the first to post a reply below: